Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Breast Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Breast Neoplasm

Cancer Family

Breast Neoplasm

CI-CAN-00000007Explore in graph →

Non-malignant2,894 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Overview
Statistics
Survival
Genomics33
Variants & evidence310
Drugs79
Trials13867
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.
· Clin Breast Cancer · 2013 · PMID 23218766 · validated civic_curation pubmed
High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.
· Med Oncol · 2012 · PMID 22544540 · validated civic_curation pubmed
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
· Cancer Cell · 2007 · PMID 17936563 · validated civic_curation pubmed
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
· Clin Cancer Res · 2013 · PMID 23658459 · validated civic_curation pubmed
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
· Clin Cancer Res · 2007 · PMID 17202311 · validated civic_curation pubmed
Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
· Breast J · 2017 · PMID 28079291 · validated civic_curation pubmed
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
· JCO Precis Oncol · 2024 · PMID 38603651 · validated civic_curation

Showing 176–200 of 268 publications

← Previous
1
…
7
8
9
10
11
Next →

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.

· Breast Cancer Res · 2017 · PMID 28183331 · validated civic_curation pubmed

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

· JCO Precis Oncol · 2024 · PMID 38354330 · validated civic_curation pubmed

Biomarkers for the clinical management of breast cancer: international perspective.

· Int J Cancer · 2013 · PMID 23280579 · validated civic_curation pubmed

Therapeutic targeting of cancers with loss of PTEN function.

· Curr Drug Targets · 2014 · PMID 24387334 · validated civic_curation pubmed

AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients.

· Dis Markers · 2013 · PMID 24167368 · validated civic_curation pubmed

Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.

· Cancer Biomark · 2017 · PMID 28269754 · validated civic_curation pubmed

A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.

· Oncol Lett · 2013 · PMID 24137399 · validated civic_curation pubmed

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.

· Mol Cancer Ther · 2015 · PMID 26351323 · validated civic_curation pubmed

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

· Ann Oncol · 2015 · PMID 25878190 · validated civic_curation pubmed

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

· Hum Mutat · 2008 · PMID 18951446 · validated civic_curation pubmed

De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.

· Hum Mutat · 2005 · PMID 16088935 · validated civic_curation pubmed

Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.

· JCO Precis Oncol · 2017 · PMID 29623306 · validated civic_curation pubmed

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.

· Oncoscience · 2016 · PMID 27489863 · validated civic_curation pubmed

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

· Nat Med · 2024 · PMID 38710951 · validated civic_curation pubmed

Breast cancer in a RAD51D mutation carrier: case report and review of the literature.

· Clin Breast Cancer · 2015 · PMID 25445424 · validated civic_curation pubmed

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.

· Onco Targets Ther · 2016 · PMID 27445490 · validated civic_curation pubmed

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.

· Oncotarget · 2017 · PMID 28978004 · validated civic_curation pubmed

Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification.

· J Natl Compr Canc Netw · 2017 · PMID 29223982 · validated civic_curation pubmed